Literature DB >> 21436265

The spectrum of subclinical Best vitelliform macular dystrophy in subjects with mutations in BEST1 gene.

Giuseppe Querques1, Jennyfer Zerbib, Rossana Santacroce, Maurizio Margaglione, Nathalie Delphin, Lea Querques, Jean-Michel Rozet, Josseline Kaplan, Eric H Souied.   

Abstract

PURPOSE: To describe the morphologic and functional characteristics of subclinical Best vitelliform macular dystrophy (VMD) in subjects with mutation in the BEST1 gene.
METHODS: Best-corrected visual acuity (BCVA), funduscopic appearance, fundus autofluorescence (FAF), spectral-domain optical coherence tomography (SD-OCT), and electro-oculography (EOG) were assessed in 23 consecutive subjects from nine unrelated families with known mutations in the BEST1 gene (eight distinct BEST1 mutations).
RESULTS: Six subjects were identified with BEST1 mutations (three male, three female; aged 8 to 30 years) without clinically detectable (subclinical) Best VMD (absence of both symptoms and funduscopic lesions). All six subjects showed 20/20 BCVA and normal FAF findings. In these 6 of 26 subjects from five different families, we found five distinct mutations in the BEST1 gene. In three (six eyes) out of these six subjects with BEST1 gene mutations (two families: p.G15D; p.A243V), SD-OCT showed overall normal findings. In the other three subjects (six eyes) with BEST1 gene mutations (three families: p.V9A; p.R92C; p.I230T), we found, on SD-OCT, a thicker and more reflective appearance of the layer between the retinal pigment epithelium and the interface of inner segments and outer segments of the photoreceptor (the Verhoeff's membrane). EOG showed a reduced light-peak:dark-trough ratio in 5 of 12 eyes. Changes on SD-OCT were present in the absence of EOG abnormalities (two of six eyes), and vice versa (one of six eyes).
CONCLUSIONS: Subclinical Best VMD (absence of both symptoms and funduscopic lesions) in subjects with BEST1 mutation may vary from the absence of any morphologic and functional abnormalities to the presence of specific SD-OCT and EOG changes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21436265     DOI: 10.1167/iovs.10-6500

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Quantitative fundus autofluorescence and optical coherence tomography in best vitelliform macular dystrophy.

Authors:  Tobias Duncker; Jonathan P Greenberg; Rithambara Ramachandran; Donald C Hood; R Theodore Smith; Tatsuo Hirose; Russell L Woods; Stephen H Tsang; François C Delori; Janet R Sparrow
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-13       Impact factor: 4.799

2.  Retinal structure in young patients aged 10 years or less with Best vitelliform macular dystrophy.

Authors:  Patrik Schatz; Dror Sharon; Sermed Al-Hamdani; Sten Andréasson; Michael Larsen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-05       Impact factor: 3.117

3.  Outer retinal structure in best vitelliform macular dystrophy.

Authors:  David B Kay; Megan E Land; Robert F Cooper; Adam M Dubis; Pooja Godara; Alfredo Dubra; Joseph Carroll; Kimberly E Stepien
Journal:  JAMA Ophthalmol       Date:  2013-09       Impact factor: 7.389

4.  Multimodal analysis of the progression of Best vitelliform macular dystrophy.

Authors:  Giuseppe Querques; Jennyfer Zerbib; Anouk Georges; Nathalie Massamba; Raimondo Forte; Lea Querques; Jean-Michel Rozet; Josseline Kaplan; Eric H Souied
Journal:  Mol Vis       Date:  2014-04-27       Impact factor: 2.367

5.  BEST1 gene therapy corrects a diffuse retina-wide microdetachment modulated by light exposure.

Authors:  Karina E Guziewicz; Artur V Cideciyan; William A Beltran; András M Komáromy; Valerie L Dufour; Malgorzata Swider; Simone Iwabe; Alexander Sumaroka; Brian T Kendrick; Gordon Ruthel; Vince A Chiodo; Elise Héon; William W Hauswirth; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-05       Impact factor: 11.205

6.  Next generation sequencing identifies novel disease-associated BEST1 mutations in Bestrophinopathy patients.

Authors:  Thong T Nguyen; B Poornachandra; Anshuman Verma; Ruchir A Mehta; Sameer Phalke; Rajani Battu; Vedam L Ramprasad; Andrew S Peterson; Arkasubhra Ghosh; Somasekar Seshagiri
Journal:  Sci Rep       Date:  2018-07-05       Impact factor: 4.379

7.  Impaired Bestrophin Channel Activity in an iPSC-RPE Model of Best Vitelliform Macular Dystrophy (BVMD) from an Early Onset Patient Carrying the P77S Dominant Mutation.

Authors:  Arnau Navinés-Ferrer; Sheila Ruiz-Nogales; Rafael Navarro; Esther Pomares
Journal:  Int J Mol Sci       Date:  2022-07-04       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.